CompletedPhase 2

Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection

Gabon54 participantsStarted 2018-07-31

Plain-language summary

Open labelled, non randomized study to evaluate the effects of Artemisinin based Combined Therapies(ACTs) on schistosomiasis since Praziquantel (PZQ) which is presently the drug of choice for treating Schistosomiasis (STS), is ineffective on immature stages and there is known parasite resistance. ACTs when combined with PZQ, targeting different stages of the life cycle has shown some effectivity.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Malaria infection diagnosed by Rapid Diagnostic Tests (RDTs) or thick blood smear * Urinary schistosomiasis diagnosed by presence of Schistosoma haematobium eggs in the urine before malaria treatment * Written informed consent Exclusion Criteria: * Patients treated with PZQ during the previous 6 weeks * Known intolerance /allergy to any study drug * Pregnancy

What they're measuring

Egg Reduction Rate (ERR)

Timeframe: Day 28

Egg Reduction Rate (ERR)

Timeframe: Day 42

Trial details

NCT IDNCT04264130

SponsorCentre de Recherche Médicale de Lambaréné

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-12-31

View on ClinicalTrials.gov More Schistosomiasis Haematobia trials